Analyst Scoreboard: 5 Ratings For Axonics

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Axonics AXNX in the last three months.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Axonics, presenting an average target of $70.0, a high estimate of $75.00, and a low estimate of $63.00. Experiencing a 6.98% decline, the current average is now lower than the previous average price target of $75.25.

Deciphering Analyst Ratings: An In-Depth Analysis

A clear picture of Axonics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Axonics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Axonics compared to the broader market.
• Price Targets: Delving into movements, analysts provide estimates for the future value of Axonics's stock. This analysis reveals shifts in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Axonics's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Axonics analyst ratings.

Unveiling the Story Behind Axonics

Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.

Unraveling the Financial Story of Axonics

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: Over the 3 months period, Axonics showcased positive performance, achieving a revenue growth rate of 32.27% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Axonics's net margin excels beyond industry benchmarks, reaching 4.22%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Axonics's ROE excels beyond industry benchmarks, reaching 0.65%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Axonics's ROA excels beyond industry benchmarks, reaching 0.6%. This signifies efficient management of assets and strong financial health.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.

The Core of Analyst Ratings: What Every Investor Should Know

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.